Aberdeen Group
CRBP icon

Aberdeen Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Aberdeen Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Hold
1,321,750
– – 0.02% 548
2025
Q4 		$10.8M Buy
1,321,750
+1,133,519
+602% +$14M 0.02% 595
2025
Q3 		$2.38M Buy
188,231
+116,005
+161% +$1.1M ﹤0.01% 765
2025
Q2 		$498K Buy
72,226
+45,332
+169% +$329K ﹤0.01% 884
2025
Q1 		$143K Hold
26,894
– – ﹤0.01% 932
2024
Q4 		$317K Hold
26,894
– – ﹤0.01% 892
2024
Q3 		$555K Buy
26,894
+21,751
+423% +$1.11M ﹤0.01% 850
2024
Q2 		$233K Hold
5,143
– – ﹤0.01% 917
2024
Q1 		$202K Buy
+5,143
New +$127K ﹤0.01% 929

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Aberdeen Group's CRBP Position: Q1 2026 in Review

Aberdeen Group held its Corbus Pharmaceuticals (CRBP) position steady in Q1 2026 at 1,321,750 shares worth $12.4M. The position accounts for 0.02% of the portfolio, ranked #548.

Aberdeen Group first reported a position in CRBP in Q1 2024 and has held it in 9 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Aberdeen Group held 1,321,750 shares of Corbus Pharmaceuticals worth $12.4M as of Q1 2026.
  • Aberdeen Group left its Corbus Pharmaceuticals share count unchanged in Q1 2026.
  • Corbus Pharmaceuticals made up 0.02% of Aberdeen Group's portfolio in Q1 2026, its #548 holding.
  • Aberdeen Group first reported a position in Corbus Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.